個人簡介：
? ? ? 現(xiàn)任中山大學(xué)附屬第七醫(yī)院副研究員,，碩士生導(dǎo)師,，中山大學(xué)高層次人才計劃引進(jìn)人才。于2017年獲得香港大學(xué)病理學(xué)博士,。曾于2017-2021年于香港大學(xué)病理系擔(dān)任博士后, 2021年2月通過中山大學(xué)引進(jìn)人才加入中山大學(xué)附屬第七醫(yī)院科研中心任職,。目前主要研究方向包括：1,、腫瘤干細(xì)胞的調(diào)控機制研究,；2、腫瘤耐藥機制及治療靶點研究,；3,、利用肺癌類器官模型進(jìn)行腫瘤微環(huán)境及腫瘤免疫相關(guān)研究。主要研究成果以通訊或（共同）第一作者身份發(fā)表在Elife, Theranostics, 和Cell Death & Diseases等雜志上,。擔(dān)任Cancer Letters等雜志審稿人,。
?
教育背景：
2004/09-2009/07? 中山大學(xué), 預(yù)防醫(yī)學(xué) 學(xué)士
2010/01-2012/05? 圣約翰大學(xué) (St. John's University) 毒理學(xué) 碩士
2012/09-2017/02? 香港大學(xué) 病理學(xué) 博士
?
工作經(jīng)歷：
2017/02-2021/01? 香港大學(xué)，病理系 博士后
2021/02-今? ? ? ? ? ? ??中山大學(xué)附屬第七醫(yī)院 副研究員 碩士生導(dǎo)師
?
主要研究方向:
1. 腫瘤干細(xì)胞的調(diào)控機制研究,。
2. 腫瘤耐藥機制及治療靶點研究,。
3. 利用肺癌類器官模型進(jìn)行腫瘤微環(huán)境及腫瘤免疫相關(guān)研究。
?
榮譽和獎勵:
2021/02 中山大學(xué)人才
2018/02 香港大學(xué)李嘉誠醫(yī)學(xué)院病理系 “Chan To Haan Prize for Research Postgraduate Student in Pathology”獎金 1萬港幣（2018年度病理系2位獲獎?wù)咧唬?/span>
2014/04,、2016/04,、 2018/04、 2020/11? 香港大學(xué)海外學(xué)術(shù)會議基金
2014/07? 香港大學(xué)李嘉誠醫(yī)學(xué)院病理系最佳研究生學(xué)術(shù)報告獎,。 （2014年度唯一獲獎?wù)撸?/span>
2014/06? 香港大學(xué)李嘉誠醫(yī)學(xué)院獎學(xué)金 “The YS and Christabel Lung Postgraduate Scholarship” 2.1萬港幣
2012/05? 圣約翰大學(xué) “Certificate of Academic excellence”（2012年度毒理系唯一獲獎?wù)撸?/span>
?
科研論文：
1. Si-Qi Wang, Jing Liu, Jing Qin, Yun Zhu, Vicky Pui-Chi Tin, Judy Wai Ping Yam, Maria Pik Wong, Zhi-Jie Xiao. CAMK2A supported Tumor Initiating Cells of Lung Adenocarcinoma by upregulating SOX2 through EZH2 Phosphorylation. Cell Death & Disease. 2020 Jun 1;11(6):410. doi: 10.1038/s41419-020-2553-6. （Corresponding author）
2. Jun-Jiang Chen*, Zhi-Jie Xiao*, Xiaojing Meng, Yan Wang, Mei Kuen Yu, Wen Qing Huang, Xiao Sun, Hao Chen, Yong-Gang Duan, Maria Pik Wong, Hsiao Chang Chan, Fei Zou, Ye Chun Ruan. MRP4 sustains Wnt/β-catenin signaling for pregnancy, endometriosis and endometrial cancer. Theranostics 2019; 9(17):5049-5064. doi:10.7150/thno.32097 (*Co-first author)
3. Zhi-Jie Xiao, Jing Liu, Si-Qi Wang, Yun Zhu, Xu-Yuan Gao, Vicky Pui-Chi Tin, Jing Qin, Jun-Wen Wang, Maria Pik Wong. NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma. Elife. 2017 Jul 24;6. pii: e26733. doi: 10.7554/eLife.26733.
4. Yun-Kai Zhang, Chunling Dai, Chun-Gang Yuan, Hsiang-Chun Wu, Zhijie Xiao, Zi-Ning Lei, Dong-Hua Yang , X Chris Le, Liwu Fu, Zhe-Sheng Chen. Establishment and characterization of arsenic trioxide resistant KB/ATO cells. Acta Pharm Sin B. 2017 Sep;7(5):564-570. doi: 10.1016/j.apsb.2017.04.001.
6. Jing Liu, Zhijie Xiao, Sunny Kit-Man Wong, Vicky Pui-Chi Tin, Ka-Yan Ho, Junwen Wang, Mai-Har Sham, Maria Pik Wong. Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells. Oncotarget. 2013 4(10):1698-1711.
7. Jun-Jiang Chen, Atish Patel, Kamlesh Sodani, Zhi-Jie Xiao, Amit K Tiwari, Dong-Mei Zhang, Ying-Jie Li, Dong-Hua Yang, Wen-Cai Ye, Si-Dong Chen, Zhe-Sheng Chen. bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). PLoS One. 2013 ;8(9):e74573.
8. Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ, Diao RY, Wang Y, Fok KL, Tsang LL, Yu MK, Zhang XH, Chung YW, Ye L, Zhao MY, Guo JH, Xiao ZJ, Lan HY, Ng CF, Lau KM, Cai ZM, Jiang WG, Chan HC. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene. 2013;32(18):2282-91, 2291.
9. Amit K Tiwari , Kamlesh Sodani, Chun-Ling Dai, Alaa H Abuznait, Satyakam Singh, Zhi-Jie Xiao, Atish Patel, Tanaji T Talele, Liwu Fu, Amal Kaddoumi, James M Gallo, Zhe-Sheng Chen. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett. 2013 28; 328(2):307-17.
10. Dong-Mei Zhang , Chang Shu, Jun-Jiang Chen, Kamlesh Sodani, Jiao Wang, Jaya Bhatnagar, Ping Lan, Zhi-Xiong Ruan, Zhi-Jie Xiao, Suresh V Ambudkar, Wei-Min Chen, Zhe-Sheng Chen, Wen-Cai Ye. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm. 2012 59(11):3147-59.
?
11. Jun-Jiang Chen , Yue-Li Sun, Amit K Tiwari, Zhi-Jie Xiao, Kamlesh Sodani, Dong-Hua Yang, Saraubh G Vispute, Wen-Qi Jiang, Si-Dong Chen, Zhe-Sheng Chen. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of MRP7 (ABCC10) transporter. Cancer Sci. 2012 11; 103(8):1531-7.
?
12. Kamlesh Sodani , Amit K Tiwari, Satyakam Singh, Atish Patel, Zhi-Jie Xiao, Jun-Jiang Chen, Yue-Li Sun, Tanaji T Talele, Zhe-Sheng Chen. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol. 2012 15; 83(12):1613-22.
?
個人郵箱: